Group 1 - The Australian rare-earths producer is set to consider both internal and external candidates for the position succeeding Lacaze [1] - Lacaze will remain with the company until the end of June [1]

President Trump's campaign to exert more control over the Federal Reserve ramped up over the weekend. Here are the basics on the situation. ...

The Trump administration has been negotiating for months to bring more high-tech chip manufacturing to the U.S. ...

Group 1 - Capital One Finance has agreed to pay $425 million over claims it misled consumers about a high-yield savings program [1]

The latest monthly World Agricultural Supply and Demand Estimates report shows higher ending stocks for corn and soybeans, running counter to what markets expected. ...

The ECB is very unlikely to raise its key interest rate this year, with a weaker dollar among a number of potential developments keeping eurozone inflation low, Bank of France Governor Francois Viller... ...

Core Insights - The European plane maker delivered 793 commercial aircraft to 91 customers last year, aligning with the company's guidance of approximately 790 deliveries [1]

Core Insights - Publicly traded drug developers raised over $13 billion in share sales during the fourth quarter, marking the highest amount in more than four years [1] Group 1 - The significant increase in share sales indicates a robust market for drug developers, reflecting investor confidence in the sector [1] - This surge in capital raising may provide companies with the necessary funds to invest in research and development, potentially leading to new drug innovations [1] - The fourth quarter's performance contrasts with previous periods, suggesting a shift in market dynamics for publicly traded pharmaceutical companies [1]

U.S. banks are entering the new year on solid footing after a strong 2025, and analysts say that momentum should continue, barring any unforeseen shocks. ...

Optimism about its growing AI business gave the Google parent entry to a rarefied club. ...